Elufor capsules 200mg, No. 12

• Acute bacterial diarrhea, proceeding without deterioration of the general condition, fever, intoxication.

Inside.

The capsule should be swallowed whole with a little water.

Adults: 1 capsule 200 mg 4 times a day (interval between doses 6 hours).

Children from 6 to 18 years old: 1 capsule 200 mg 3-4 times a day (interval between doses 6-8 hours).

Children from 3 to 6 years old: 1 capsule 200 mg 3 times a day (interval between doses 8 hours)

The duration of the course of treatment is 5-7 days, but not more than 7 days.

If there is no improvement within the first 3 days of taking, then you should consult a doctor.

Use the drug only according to the method of administration and in the doses indicated in the instructions. If necessary, please consult your doctor before using this medication.

Active ingredient: nifuroxazide - 200.0 mg.

Excipients: sucrose - 70.0 mg; microcrystalline cellulose - 41.5 mg; corn starch - 35.0 mg; magnesium stearate - 3.5 mg.

The composition of the capsule body: quinoline yellow dye - 0.7500%; dye sunset yellow - 0.0059%; titanium dioxide - 2.0000%; gelatin - up to 100%.
The composition of the capsule cap: quinoline yellow dye - 0.7500%; sunset yellow dye - 0.0059%; titanium dioxide - 2.0000%; gelatin - up to 100%.

• hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug;

• children under 3 years of age (for this dosage form);

• pregnancy;

• deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption.

Trade name:

Elufor

International non-proprietary name:

nifuroxazide

Dosage form:

capsules

Composition for 1 capsule:

Active ingredient: nifuroxazide - 200.0 mg.

Excipients: sucrose - 70.0 mg; microcrystalline cellulose - 41.5 mg; corn starch - 35.0 mg; magnesium stearate - 3.5 mg.

The composition of the capsule body: quinoline yellow dye - 0.7500%; dye sunset yellow - 0.0059%; titanium dioxide - 2.0000%; gelatin - up to 100%.
The composition of the capsule cap: quinoline yellow dye - 0.7500%; sunset yellow dye - 0.0059%; titanium dioxide - 2.0000%; gelatin - up to 100%.

Description

Hard gelatin capsules No. 0. The body and lid are yellow, opaque.
The contents of the capsules are a mixture of powder and yellow granules. It is allowed to seal the contents of the capsules into lumps, which crumble when pressed.

Pharmacotherapeutic group:

antimicrobial agent - nitrofuran

ATX code:

A07AX03

Pharmacological properties

Pharmacodynamics
Nifuroxazide - is a derivative of nitrofuran, has antimicrobial effect. Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae, Proteus indologenes.
Nifuroxazide resistant: Klebsiella spp, Proteus mirabilis, Providencia spp., Pseudomonas spp. Presumably blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. Does not disturb the balance of intestinal microflora.
In case of acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokinetics
After oral administration, nifuroxazide is practically not absorbed from the gastrointestinal tract and has no systemic effect; 99% of the dose taken remains in the intestine and has its antimicrobial effect there. Nifuroxazide is excreted by the intestines: 20% is unchanged, and the rest of nifuroxazide is chemically altered.

Indications for use

• Acute bacterial diarrhea, proceeding without deterioration of the general condition, fever, intoxication.

Contraindications

• hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug;

• children under 3 years of age (for this dosage form);

• pregnancy;

• deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption.

Application during pregnancy and during breastfeeding

In animal studies, no teratogenic effect was found. However, it is not recommended to take nifuroxazide during pregnancy as a precautionary measure. During the lactation period, it is possible to continue breastfeeding in the case of a short course of drug treatment. It is necessary to consult a doctor.

Method of administration and dosage

Inside.

The capsule should be swallowed whole with a little water.

Adults: 1 capsule 200 mg 4 times a day (interval between doses 6 hours).

Children from 6 to 18 years old: 1 capsule 200 mg 3-4 times a day (interval between doses 6-8 hours).

Children from 3 to 6 years old: 1 capsule 200 mg 3 times a day (interval between doses 8 hours)

The duration of the course of treatment is 5-7 days, but not more than 7 days.

If there is no improvement within the first 3 days of taking, then you should consult a doctor.

Use the drug only according to the method of administration and in the doses indicated in the instructions. If necessary, please consult your doctor before using this medication.

Side effect

Allergic reactions (skin rash, urticaria, Quincke's edema, anaphylactic shock). If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects that are not indicated in the instructions, inform your doctor.

Overdose

Overdose symptoms are not known. Treatment is symptomatic.

Interaction with other medicinal products

Simultaneous use with drugs that cause the development of disulfiram-like reactions, drugs that inhibit the function of the central nervous system is not recommended.
If you are taking other medications (including over-the-counter), consult your doctor before using Elufor.

special instructions

When treating diarrhea, rehydration therapy should be carried out concurrently with nifuroxazide therapy.
In the case of bacterial diarrhea with signs of systemic damage (deterioration of the general condition, fever, symptoms of intoxication or infection), you should consult a doctor about deciding on the use of systemic antimicrobials.
The daily dose of the drug 800 mg contains 0.023 XE.
During therapy with Elufor, the use of alcohol is prohibited.
If symptoms of an allergic reaction appear (including shortness of breath, rash, itching), you should stop taking the drug and consult a doctor.

Influence on the ability to drive vehicles and mechanisms

The drug does not affect the ability to drive vehicles and mechanisms.

Release form

Capsules 200 mg.
On 5, 6 or 10 capsules in a blister strip packaging from a film of polyvinyl chloride and printed aluminum foil varnished.
10, 20, 30, 40, 50 or 100 capsules in jars made of polyethylene terephthalate for medicines, sealed with screw caps with first opening control or a push-and-turn system made of polypropylene or polyethylene or polypropylene jars for medicines, sealed with tightening caps with control of the first opening made of polyethylene or polypropylene cans for medicines, sealed with tightened lids with control of the first opening made of high-pressure polyethylene.
One can or 1, 2, 3, 4, 5, 6 or 10 blisters together with instructions for use are placed in a cardboard package (pack).

Storage conditions

At a temperature not higher than 25 ? C.
Keep out of the reach of children.

Shelf life

3 years. Do not use the drug after the expiration date.

Vacation conditions

Available without a prescription.

Manufacturer

LLC 'Ozon'
Legal address: 445351, Russia, Samara region., Zhigulevsk, st. Pesochnaya, 11.
Address of production, including for correspondence and receipt of claims:
445351, Russia, Samara region, Zhigulevsk, st. Gidrostroiteley, 6.